NSE: CIPLA · 23 October 2026
- Cipla Ltd shares edged down by 0.44% to close at ₹1,325.00 on Thursday, moving within a day's range of ₹1,314.10 and ₹1,337.90 after opening higher at ₹1,335.00.
- Cipla announced that a routine current Good Manufacturing Practices inspection conducted by the USFDA at its wholly-owned subsidiary InvaGen Pharmaceuticals' manufacturing facility in Hauppauge, New York, successfully concluded between October 19 and October 22, 2026. The inspection resulted in zero Form 483 observations, highlighting strong compliance standards at the plant.
- Trading volume was 1.22 times the 20-day average daily volume.
Why is CIPLA share price falling on 23 October 2026?
Cipla Ltd shares edged down by 0.44% to close at ₹1,325.00 on Thursday, moving within a day's range of ₹1,314.10 and ₹1,337.90 after opening higher at ₹1,335.00.
The broader market and sectoral backdrop remained weak, putting pressure on healthcare counters. The benchmark Nifty declined by 0.90%, while the Nifty Pharma sector index underperformed with a sharp drop of 1.49%. Cipla's modest intraday decline aligned with this broader sectoral pullback, coming on the back of a 0.23% loss over the preceding 5 trading days and a 4.19% correction over the last 20 trading days.
Company disclosures showed that the stock's recent price action coincides with operational updates, including the announcement on 23rd October 2026 regarding a routine current Good Manufacturing Practices inspection by the USFDA at the InvaGen Pharmaceuticals manufacturing facility in Hauppauge, New York, which concluded with zero Form 483 observations. However, given the muted intraday price movement, no single confirmed operational catalyst directly drove today's minor correction, pointing instead to general sector-wide consolidation.
11.57 lakh shares traded by 23 October 2026 · 03:00 PM IST. This compares with a 20-day average daily volume of 9.46 lakh shares (1.22 times). The five-day average daily volume was 10.97 lakh shares. Separately, the NSE report for 22 October 2026 showed 3.46 lakh shares delivered, representing 54.12% of that day’s traded volume. The same report recorded 24,802 trades.
The stock's minor 0.44% decline lacks a direct single catalyst and is best viewed as a continuation of recent short-term weakness amid a broader downturn in pharmaceutical indices, despite clean USFDA inspection updates.
Latest Company Developments
Cipla announced that a routine current Good Manufacturing Practices inspection conducted by the USFDA at its wholly-owned subsidiary InvaGen Pharmaceuticals' manufacturing facility in Hauppauge, New York, successfully concluded between October 19 and October 22, 2026. The inspection resulted in zero Form 483 observations, highlighting strong compliance standards at the plant.
Maintaining clean regulatory inspection records at key manufacturing sites is vital for uninterrupted export operations and sustaining product pipelines in the US market.
Invagen Pharmaceuticals Inc., a wholly-owned subsidiary of Cipla, entered into an exclusive licensing and supply partnership with Qilu Pharmaceutical for QL2107, a biosimilar to Keytruda (pembrolizumab), targeting the United States market. Under the agreement, Qilu will handle development and manufacturing, while Cipla USA Inc. will lead commercialization efforts.
This partnership strengthens Cipla's oncology and biosimilar footprint in regulated international markets, supporting long-term specialty portfolio growth.
Mr. Venkata Sai Mungara transitioned from his role as Global Head Supply Chain to Chief of Manufacturing and Supply Chain Operations of Cipla USA Inc., a wholly-owned subsidiary, effective 1st October 2026, thereby ceasing to be a Senior Management Personnel of the parent company.
Internal leadership realignments across key overseas subsidiaries help streamline operational execution in core international territories.
USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA.
Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 20.78% on 30 September 2026. This compares with 20.56% on 30 June 2026, a change of +0.22 percentage points.
The filing reported 46 MF/UTI holders.
What to Watch Next
- Upcoming financial results and board meeting scheduled for October 2026 to review quarterly performance.
- Execution progress on the US biosimilar partnership pipeline with Qilu Pharmaceutical.
- Delivery volume trends and sustenance above key technical support levels near the day's low of ₹1,314.10.
- Regulatory updates regarding other key manufacturing facilities such as Pithampur and InvaGen.
Other Dated Coverage
More CIPLA news and dated analysis →
Frequently Asked Questions
What is the latest CIPLA company news?
Cipla announced that a routine current Good Manufacturing Practices inspection conducted by the USFDA at its wholly-owned subsidiary InvaGen Pharmaceuticals' manufacturing facility in Hauppauge, New York, successfully concluded between October 19 and October 22, 2026. The inspection resulted in zero Form 483 observations, highlighting strong compliance standards at the plant.
How strong was CIPLA’s trading volume?
11.57 lakh shares traded, 1.22 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 · 03:00 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.